"Compared with those prescribed lifestyle intervention for obesity, adolescents prescribed either liraglutide (Saxenda; Novo Nordisk) or semaglutide (Wegovy; Novo Nordisk) had a 33% lower risk of suicidality over 12 months of follow-up after controlling for potential baseline confounders."[1]

[1]https://www.tctmd.com/news/defying-earlier-glp-1-data-study-...

It's not even the second time around now, liraglutide was approved a decade ago.